Skip to main content
SGP logo

SpyGlass Pharma, Inc. (SGP) Stock: Price, Forecast & Analyst Target

SpyGlass Pharma, Inc. (SGP) — MoonshotScore 64/100 (Fair band), calculated Nov 18, 2026. Price $30.78 (+3.71%), as of the Nov 19, 2026 trading session; market cap $1.03B.

Educational signal · not a buy or sell recommendation · How to read this

$30.78 +$1.10 (+3.71%) Market Cap $1.03B

SpyGlass Pharma, Inc. · SGP · NASDAQ

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company focused on developing innovative therapeutic approaches for chronic eye conditions. Its flagship Bimatoprost Drug Pad-IOL System aims to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension during cataract surgery.

Price as of Nov 19, 2026

Key Statistics

64 of 100

MoonshotScore v2 · SpyGlass Pharma (SGP)

Fair
Business Quality Average (41)
Financial Safety Fortress (93)
Valuation Full (52)
Growth Durability Fading (36)
Momentum Surging (89)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fortress balance sheet, but weak growth and a full valuation; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Surging.

  • EPS beat 0 of the last 3 reports
  • Altman Z 39.68 · Piotroski F 1
  • ROE -43.0% · ROA -27.3% · current ratio 15.24

Helping: balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SGP (57 recorded, newest six shown)
RecordedScoreBand
64Fair
65Strong
66Strong
66Strong
64Fair
64Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$30.78
Change on the day+3.71%
Market capitalisation$1.03B—
Shares traded on the day86.4K

Price & events

Other perspectives

Council score for SpyGlass Pharma (SGP): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Strong
Valuation Neutral
Growth Durability Weak
Momentum Strong

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company less favourably than the MoonshotScore does: Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is SpyGlass Pharma (SGP), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. SpyGlass Pharma, Inc. (SGP) is listed on NASDAQ. It employs 88 people. The market values it at $1.03B.

2 · Latest results

What do the latest results show for SpyGlass Pharma (SGP)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 3 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for SpyGlass Pharma (SGP)?

Short answer

The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. The distress and quality screens read Altman Z 39.68 · Piotroski F 1. Trailing ratios: ROE -43.0% · ROA -27.3% · current ratio 15.24.

Data-derived red flags

  • Negative return on equity (-43.0%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at SpyGlass Pharma (SGP)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $0.00 · EPS -2.73 · 0 analysts. Current published price targets run low $37.00 · high $44.00 · consensus $40.00 · median $39.00 against a quoted price of $30.78 (as of Nov 19, 2026).

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for SGP.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does SpyGlass Pharma compare with its peers?

Short answer

SpyGlass Pharma's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eton Pharmaceuticals, Inc. (ETON) Same industry, near in market value$61.99 Nov 18, 2026$1.79B98 5-pillar Nov 18, 2026
Nurix Therapeutics, Inc. (NRIX) Same industry, near in market value$14.10 Nov 18, 2026$1.54B97 5-pillar Nov 18, 2026
Innoviva, Inc. (INVA) Same industry, near in market value$18.40 Nov 18, 2026$1.31B96 5-pillar Nov 18, 2026
Harmony Biosciences Holdings, Inc. (HRMY) Same industry, near in market value$33.11 Nov 18, 2026$1.94B96 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
AnaptysBio, Inc. (ANAB) Same industry, near in market value$47.40 Nov 19, 2026$1.41B76 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
LB Pharmaceuticals Inc (LBRX) Same industry, near in market value$40.04 Nov 19, 2026$1.30B69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
Vor Biopharma, Inc. (VOR) Same industry, near in market value$18.52 Nov 19, 2026$1.14B66 5-pillar Nov 18, 2026
SpyGlass Pharma (SGP) — this page$30.78$1.03B64
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$37.00 – $44.00
Consensus target
$40.00
Median target
$39.00
Revenue estimate
$0.00
EPS estimate
$-2.73

Consensus record · Captured .

Measured against a quoted price of $30.78 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SGP in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SGP in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about SpyGlass Pharma (SGP)?

Read these with our analysis →

Investor Questions: SGP Stock

These answers are editorial: 1 of these 9 answers is drawn from the SGP research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for SGP?

SGP carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. SpyGlass Pharma, Inc. is an advanced biopharmaceutical company focused on developing innovative therapeutic approaches for chronic eye conditions.

Is SGP a good stock to buy?

Stock Expert AI does not rate SGP buy, sell or hold. SpyGlass Pharma, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SGP stock price today?

The last price recorded for SpyGlass Pharma, Inc. (SGP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the SGP price target?

The analyst consensus price target for SpyGlass Pharma, Inc. (SGP), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for SGP?

The main risks for SpyGlass Pharma, Inc. are inherent to its nature as a clinical-stage biopharmaceutical company heavily reliant on a single lead product, the Bimatoprost Drug Pad-IOL System.

What are the key factors to evaluate for SGP?

SpyGlass Pharma, Inc. (SGP) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Focus on chronic eye conditions with its flagship Bimatoprost Drug Pad-IOL System, addressing a significant unmet medical need in ophthalmology. Not financial advice.

How frequently does SGP data refresh on this page?

SGP's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SGP's recent stock price performance?

SpyGlass Pharma, Inc. (SGP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Bimatoprost Drug Pad-IOL System addressing a significant unmet need in chronic eye conditions. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SGP overvalued or undervalued right now?

SpyGlass Pharma, Inc. (SGP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 9 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.